About MAP Pharmaceuticals
MAP Pharmaceuticals is a company based in Mountain View (United States) founded in 2003 by Paul Boyd was acquired by Allergan in January 2013.. MAP Pharmaceuticals has raised $50 million across 1 funding round from investors including D. E. Shaw Group, Allergan and MINITOTO. MAP Pharmaceuticals operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Mountain View, United States
- Founders Paul Boyd
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Map Pharmaceuticals, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$50 M (USD)
in 1 rounds
-
Latest Funding Round
$50 M (USD), Series D
Mar 28, 2007
-
Investors
D. E. Shaw Group
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Allergan
(Jan 22, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of MAP Pharmaceuticals
MAP Pharmaceuticals has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Series D round of $50 million completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series D — $50.0M
-
First Round
First Round
(28 Mar 2007)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2007 | Amount | Series D - MAP Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MAP Pharmaceuticals
MAP Pharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include D. E. Shaw Group, Allergan and MINITOTO. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Online slot gaming platform is provided by MINITOTO.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MAP Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MAP Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Map Pharmaceuticals Comparisons
Competitors of MAP Pharmaceuticals
MAP Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Map Pharmaceuticals
Frequently Asked Questions about MAP Pharmaceuticals
When was MAP Pharmaceuticals founded?
MAP Pharmaceuticals was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Where is MAP Pharmaceuticals located?
MAP Pharmaceuticals is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Is MAP Pharmaceuticals a funded company?
MAP Pharmaceuticals is a funded company, having raised a total of $50M across 1 funding round to date. The company's 1st funding round was a Series D of $50M, raised on Mar 28, 2007.
What does MAP Pharmaceuticals do?
Founded in 2003 in Mountain View, United States, MAP Pharmaceuticals operated in the pharmaceutical sector, focusing on inhalation drug delivery systems. Levadex, an inhalable migraine therapy, was developed and submitted for FDA approval, alongside the TEMPO hand-held inhaler. Proprietary particle and inhalation technologies were applied to enhance existing drugs, creating pipeline opportunities. The company was acquired by Allergan in March 2013.
Who are the top competitors of MAP Pharmaceuticals?
MAP Pharmaceuticals's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Who are MAP Pharmaceuticals's investors?
MAP Pharmaceuticals has 7 investors. Key investors include D. E. Shaw Group, Allergan, MINITOTO, Pequot Capital Management, and Brookside Capital.